The short answer
Human research on cannabis for muscle spasms is concentrated in multiple sclerosis (MS) and spinal cord injury. The most consistent findings come from oral and oromucosal THC:CBD extracts, which several randomized trials link to lower patient-reported spasm frequency and less stiffness in MS. Evidence for smoked flower, for isolated CBD, and for spasm from other causes is thinner and more mixed. No cannabis product holds FDA approval for muscle spasms in the United States.
Why trial results seem to disagree
Spasticity is a velocity-dependent rise in muscle tone. A spasm is a sudden involuntary contraction. Researchers measure the first with clinician scales such as the Ashworth or Modified Ashworth, and the second with patient diaries and rating scales. Those two families of measures often pull apart, and that split drives most of the conflicting headlines.
How Quickly Does Cannabis Work for Spasms? A Route by Route Guide
- Clinician-rated tone: frequently unchanged versus placebo.
- Patient-rated spasm frequency and stiffness: improved in many trials.
- Motor function and disability scores: results range from small gains to no difference.
What the main evidence bodies report
A Cochrane review of cannabinoids for MS spasticity found low-quality evidence of a small benefit on patient-reported spasticity, with no clear effect on clinician-rated tone. The National Academies report on cannabis and health named MS spasticity among the conditions with substantial evidence of therapeutic effect, while noting that most trials used pharmaceutical extracts rather than whole flower.
cannabis oil for muscle spasms dosage
Nabiximols, an oromucosal THC:CBD spray, is the most studied product worldwide. It is approved in several countries for MS spasticity and remains unapproved in the US. Trials of smoked cannabis in MS are few and small, and CBD-only trials for spasticity have produced results close to placebo.
cannabis oil for muscle spasms dosage
Prerequisites before you read a single study
- Know which condition the trial enrolled. MS, spinal cord injury, and general spasm groups answer different questions.
- Know the product. Ratio, route, and dose change the outcome.
- Know the scale. Patient-reported and clinician-rated endpoints are not interchangeable.
How to evaluate a study on cannabis and spasm
- Identify the enrolled condition and confirm it matches your question.
- Record the exact product: THC:CBD ratio, route of delivery, and daily dose.
- Locate the primary outcome and check whether it is patient-reported or clinician-rated.
- Check the blinding method, since taste and psychoactivity can break it.
- Note the trial length. Most run 4 to 15 weeks, which limits what can be said about long-term use.
- Read the limitations paragraph and weight the conclusion against it.
Safety signals in the literature
Common adverse events in these trials include dizziness, somnolence, dry mouth, and balance problems. Cognitive effects appear more in high-THC arms. Two areas get flagged: falls in people who already have impaired mobility, and interactions with drugs that share the same liver enzymes, including some antispasticity and antiseizure medications.
Questions to bring to a clinician
- Ask whether your spasticity is a documented treatment target or a symptom of another issue.
- List your current medications, including baclofen, tizanidine, and antiseizure drugs.
- Ask what a reasonable trial period looks like and how improvement will be measured.
- Ask what side effects would mean stopping.
Bottom line
The research supports a modest, patient-reported benefit from THC:CBD extracts in MS spasticity and little else with confidence. If you read one number, read the primary endpoint and who reported it.